Quinazoline derivatives for the treatment of tumours

Abstract

The invention concerns quinazoline derivatives of Formula (I) wherein each of Q 1 , Z, m, R 1 , R 2 , R 3 and Q 2 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.

1 - 16 . (canceled) 
     
     
         17 . A method for treating solid tumour disease sensitive to inhibition of one or more non-receptor tyrosine kinases by producing an anti-invasive effect in a warm-blooded animal in need thereof comprising administering to said animal an effective non-receptor tyrosine kinase inhibiting amount of the compound:
 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline;   or a pharmaceutically-acceptable acid-addition salt thereof.   
     
     
         18 . A method for containing solid tumour disease sensitive to inhibition of one or more non-receptor tyrosine kinases by producing an anti-invasive effect in a warm-blooded animal in need thereof comprising administering to said animal an effective non-receptor tyrosine kinase inhibiting amount of the compound:
 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline;   or a pharmaceutically-acceptable acid-addition salt thereof.   
     
     
         19 . A method for inhibiting the invasiveness of solid tumour disease sensitive to inhibition of one or more non-receptor tyrosine kinases in a warm-blooded animal in need thereof comprising administering to said animal an effective non-receptor tyrosine kinase inhibiting amount of the compound:
 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline;   or a pharmaceutically-acceptable acid-addition salt thereof.   
     
     
         20 . A method for the containment of solid tumour disease sensitive to inhibition of one or more non-receptor tyrosine kinases in a warm-blooded animal in need thereof comprising administering to said animal an effective non-receptor tyrosine kinase inhibiting amount of the compound:
 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline;   or a pharmaceutically-acceptable acid-addition salt thereof.   
     
     
         21 . A method for treating solid tumour disease sensitive to inhibition of one or more non-receptor tyrosine kinases in a warm-blooded animal in need thereof by inhibition of the motility of tumour cells comprising administering to said animal an effective non-receptor tyrosine kinase inhibiting amount of the compound:
 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline;   or a pharmaceutically-acceptable acid-addition salt thereof.   
     
     
         22 . A method for treating solid tumour disease sensitive to inhibition of one or more non-receptor tyrosine kinases in a warm-blooded animal in need thereof by inhibition of the dissemination and invasiveness of cancer cells comprising administering to said animal an effective non-receptor tyrosine kinase inhibiting amount of the compound:
 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline;   or a pharmaceutically-acceptable acid-addition salt thereof.   
     
     
         23 . A method for treating a solid tumour sensitive to inhibition of one or more non-receptor tyrosine kinases in a warm-blooded animal in need thereof comprising administering to said animal an effective non-receptor tyrosine kinase inhibiting amount of the compound:
 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline;   or a pharmaceutically-acceptable acid-addition salt thereof, in combination with one or more of conventional surgery, radiotherapy and chemotherapy.   
     
     
         24 . A method for inhibiting solid tumour growth in a warm-blooded animal in need thereof comprising administering to said animal an effective tyrosine kinase inhibiting amount of the compound:
 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline;   or a pharmaceutically-acceptable acid-addition salt thereof.   
     
     
         25 . A method for treating a solid tumour disease in a warm-blooded animal in need thereof comprising administering to said animal an effective amount of the compound:
 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline;   or a pharmaceutically-acceptable acid-addition salt thereof.   
     
     
         26 . A method for inhibiting the growth of a solid tumour cell comprising contacting said cell with an inhibiting amount of the compound:
 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline;   or a pharmaceutically-acceptable acid-addition salt thereof.   
     
     
         27 . A method for inhibiting the growth of a solid tumour cell in a warm blooded animal comprising contacting said cell with an inhibiting amount of the compound:
 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline;   or a pharmaceutically-acceptable acid-addition salt thereof.   
     
     
         28 . A method for producing an anti-invasive effect by the containment and/or treatment of solid tumour disease in a warm-blooded animal in need of such treatment which comprises administering to said animal an effective amount of the compound:
 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline;   or a pharmaceutically-acceptable acid-addition salt thereof.